Identification of potential target genes of non-small cell lung cancer in response to resveratrol treatment by bioinformatics analysis

Lung cancer is the leading cause of cancer death and its incidence is ranked high in men and women worldwide. Non-small-cell lung cancer (NSCLC) adenocarcinoma is one of the most frequent histological subtypes of lung cancer. The aberration profile and the molecular mechanism driving its progression are the key for precision therapy of lung cancer, while the screening of biomarkers is essential to the precision early diagnosis and treatment of the cancer. In this work, we applied a bioinformatics method to analyze the dysregulated interaction network of microRNA-mRNA in NSCLC, based on both the gene expression data and the microRNA-gene regulation network. Considering the properties of the substructure and their biological functions, we identified the putative diagnostic biomarker microRNAs, some of which have been reported on the PubMed citations while the rest, that is, miR-204-5p, miR-567, miR-454-3p, miR-338-3p, and miR-139-5p, were predicted as the putative novel microRNA biomarker for the diagnosis of NSCLC adenocarcinoma. They were further validated by functional enrichment analysis of their target genes. These findings deserve further experimental validations for future clinical application.

Download Full-text

Frontiers of MicroRNA Signature in Non-small Cell Lung Cancer

Frontiers in Cell and Developmental Biology ◽

10.3389/fcell.2021.643942 ◽

2021 ◽

Vol 9 ◽

Author(s):

Xinping Zhu ◽

Masahisa Kudo ◽

Xiangjie Huang ◽

Hehuan Sui ◽

Haishan Tian ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Target Genes ◽

Late Onset ◽

Relative Survival ◽

Small Cell ◽

Diagnostic Tools ◽

Screening Methods ◽

Small Cell Lung

Lung cancer is the leading cause of cancer-related deaths worldwide and non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer cases. Recent advancements in diagnostic tools, surgical treatments, chemotherapies, and molecular targeted therapies that improved the therapeutic efficacy in NSCLC. However, the 5-years relative survival rate of NSCLC is only about 20% due to the inadequate screening methods and late onset of clinical symptoms. Dysregulation of microRNAs (miRNAs) was frequently observed in NSCLC and closely associated with NSCLC development, progression, and metastasis through regulating their target genes. In this review, we provide an updated overview of aberrant miRNA signature in NSCLC, and discuss the possibility of miRNAs becoming a diagnostic and therapeutic tool. We also discuss the possible causes of dysregulated miRNAs in NSCLC.

Download Full-text

Targeted Therapy for Non-Small Cell Lung Cancer

Korean Journal of Medicine ◽

10.3904/kjm.2020.95.2.78 ◽

2020 ◽

Vol 95 (2) ◽

pp. 78-88

Author(s):

Jung Sun Kim ◽

Eun Joo Kang

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Survival Benefit ◽

Target Genes ◽

Gene Mutations ◽

Therapeutic Agents ◽

Small Cell ◽

Small Cell Lung ◽

Gene Alterations

Treatment of progressive non-small cell lung cancer (NSCLC) has advanced remarkably, due in part to the development of targeted therapies. Several gene alterations, including EGFR, ALK, ROS1, and BRAF, play important roles in carcinogenesis. Therefore, many targeted agents focusing these gene alterations have been developed and proving their therapeutic efficacies in many clinical trials. Now we should test these gene mutations and should apply treatments individually and properly to ensure the maximal survival benefit of each patient. In this review, we summarize the target genes and respective therapeutic agents in NSCLC.

Download Full-text